Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Black Bear Value Partners Adam Schwartz | “Lanxess is a German specialty chemicals company that was originally spun off from Bayer 20 years ago. The management team has been focused on selling more cyclical and capital-intensive businesses and building out stickier/lower capital-intensive businesses. For example, “Mobility” (cyclical auto/tires) was ~40% of their business in 2016 and today is ~15%. Additionally, they've focused on growing their business in the US. For example, US business was ~15% of sales in 2016 and is approaching ~30% today. Over the last 3 years leverage reached ~5x debt/EBITDA. As they've sold off some of the cyclical businesses, they've reduced debt to ~3.4x as of now. This is still too high for this kind of business and management targets ~2.5x leverage and an investment grade credit rating. The core business should be able to generate ~200-250mm in free-cash flow in a more normalized environment which equates to an 11-14% free-cashflow yield. They're currently experiencing weak end-market use and generating 130-160mm in cash, which equals a 7-9% yield. This leaves out a large source of value. LXS has a JV with a put right to their partner. This has 1BB Euro value to LXS (equity value + debt owed to LXS). They exercised their put right and are now waiting for their JV partner to respond with their intentions. In any event LXS will be receiving somewhere between 500mm-1bb euros. If we conservatively assume 500mm of a cash-inflow the business is currently generating a 10-12% yield and will generate 15-20% mid-cycle yield. Once the company delevers I anticipate they will buy in a lot of stock at these levels. BSD Analysis: Lanxess remains a restructuring and margin-repair story, with portfolio simplification and cost-cutting aimed at stabilizing earnings after years of chemical-sector volatility. Specialty additives and consumer protection provide higher-margin anchors, while weaker basic-chem segments are being addressed through partnerships and divestitures. Cash flow is improving as working capital normalizes. Sentiment is washed out, but the long-term strategy is credible. If management continues delivering on execution, Lanxess has meaningful rerating potential.” | BEAR | Q3 2025 Oct 8, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
